These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 29171358)
1. The comparative pharmacokinetics of physical manipulation by crushing of Xtampza Brennan MJ; Kopecky EA; Marseilles A; O'Connor M; Fleming AB Pain Manag; 2017 Nov; 7(6):461-472. PubMed ID: 29171358 [TBL] [Abstract][Full Text] [Related]
2. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255 [TBL] [Abstract][Full Text] [Related]
3. Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza Gudin J J Opioid Manag; 2020; 16(2):127-139. PubMed ID: 32329888 [TBL] [Abstract][Full Text] [Related]
4. Oral Human Abuse Potential of Oxycodone DETERx Kopecky EA; Fleming AB; Levy-Cooperman N; O'Connor M; M Sellers E J Clin Pharmacol; 2017 Apr; 57(4):500-512. PubMed ID: 27669664 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER). Meske D; Kopecky EA; Passik S; Shram MJ J Opioid Manag; 2018; 14(5):359-372. PubMed ID: 30387859 [TBL] [Abstract][Full Text] [Related]
6. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation. Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603 [TBL] [Abstract][Full Text] [Related]
7. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation. Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. Perrino PJ; Colucci SV; Apseloff G; Harris SC Clin Drug Investig; 2013 Jun; 33(6):441-9. PubMed ID: 23677743 [TBL] [Abstract][Full Text] [Related]
9. A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin. Olatoke O; Zah V; Stanicic F; Vukicevic D; Yfantopoulos P; Thompson C; DeGeorge MK; Passik S Clinicoecon Outcomes Res; 2022; 14():119-128. PubMed ID: 35264862 [TBL] [Abstract][Full Text] [Related]
10. In Vitro Drug Release After Crushing: Evaluation of Xtampza Mayock SP; Saim S; Fleming AB Clin Drug Investig; 2017 Dec; 37(12):1117-1124. PubMed ID: 28940174 [TBL] [Abstract][Full Text] [Related]